Unternehmensübersicht
The Oncology Institute, Inc. operates as a specialized oncology provider within the United States, delivering a comprehensive range of cancer care services through its three primary segments: specialty pharmacy, patient services, and clinical trials and other related activities. This entity functions within the broader Healthcare sector, specifically categorized under the industry of Medical Care Facilities, a designation that reflects its core focus on delivering essential medical treatments and infrastructure for oncology patients. The company's current market capitalization stands at $306.40M, supported by an annualized revenue base of $502.73M and an organizational workforce comprising 641 employees. These financial and operational metrics indicate a mid-cap entity with significant revenue generation capabilities relative to its employee count, suggesting a highly efficient operational model within the specialized oncology market. The substantial revenue figure of over half a billion dollars, combined with a market cap under one billion, positions the company as a established player that relies on recurring revenue streams from its diverse service offerings rather than speculative growth narratives.
Finanzielle Gesundheit
The company reported a Total Revenue of $502.73M for the trailing twelve months, yet recorded a Net Income of -$50,305,000 and an EBITDA of -$29,139,000, highlighting a significant disparity between top-line generation and bottom-line profitability. This gap between revenue and net income reveals a substantial cost structure burden, where operating expenses and taxes likely exceed gross profits to such an extent that the company incurs a net loss of approximately 10% of its revenue. The Free Cash Flow stands at -$11,004,375, indicating that the company is currently burning cash to fund its operations and growth initiatives, which limits immediate financial flexibility for large-scale capital expenditures without external financing. Analyzing the margins, the Gross Margin is 15.2%, which suggests a moderate ability to cover direct costs of goods sold, while the Operating Margin of -4.9% and Profit Margin of -12.1% demonstrate that overhead costs and other expenses are consuming a large portion of the generated revenue. The balance sheet shows a Cash position of $33.56M against Total Debt of $103.75M, with a Debt to Equity ratio listed as N/A, implying that the company carries a leveraged profile where debt obligations significantly outweigh liquid cash reserves. The Current Ratio is 1.59, which indicates a conservative short-term liquidity position where current assets comfortably exceed current liabilities, providing a buffer against immediate financial obligations. Return on Equity and Return on Assets are both N/A or negative in nature, with the Return on Assets specifically at -13.4%, revealing that management is currently not generating positive returns on the capital base employed in the business.
Bewertungsanalyse
The valuation metrics present a complex picture with a Forward P/E of -19.38 and a Trailing P/E ratio of N/A, implying that investors are pricing the stock based on future earnings expectations that are currently negative or undefined due to the company's loss-making status. The Price to Book ratio is -19.50, a negative figure that indicates the market values the company at a significant discount to its book value, often seen in distressed or turnaround situations where assets are not generating sufficient income to justify their accounting value. Alternative valuation multiples such as the Price to Sales ratio of 0.61 and the EV/EBITDA of -12.92 suggest that the market is willing to pay roughly 61 cents for every dollar of sales, reflecting a skepticism about immediate profitability but acknowledging the revenue scale. Regarding price volatility, the 52-week high is $4.88 and the 52-week low is $1.29; without a specific current share price in the provided facts, the valuation context relies on these bounds to show the trading range experienced over the past year. The Beta value is 0.20, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting that the share price is less sensitive to general market fluctuations and may offer a defensive characteristic despite the company's financial losses.
Growth & Income
The company demonstrates robust expansion in its top line with a Revenue Growth (YoY) of 41.6%, while the Earnings Growth (YoY) is N/A due to the company's net loss position. The absence of positive earnings growth relative to revenue growth implies that the company is prioritizing market share expansion and service capacity over immediate profitability, a common strategy in capital-intensive healthcare facilities. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that all available cash flow is retained within the business to service debt or fund operations. Consequently, the overall growth and income profile is characterized by aggressive top-line scaling supported by a capital-lighter structure relative to its revenue, but it lacks the income generation component that dividend investors typically seek.